Literature DB >> 1419807

Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).

P M Mannucci1, D Bettega, M Cattaneo.   

Abstract

When patients with mild haemophilia or von Willebrand disease (vWD) are repeatedly treated with desmopressin (DDAVP) at relatively short time intervals, some of them may become less responsive or unresponsive. The development of tachyphylaxis would limit the usefulness of DDAVP in clinical management of these patients. On the other hand, tachyphylaxis is not consistent, and its patterns of development are unknown. The aim of this study was to evaluate in controlled conditions the occurrence of tachyphylaxis by giving intravenous DDAVP (0.3 microgram/kg) on four consecutive days to a selected group of patients with mild haemophilia A (n = 22) and type I vWD (n = 15). After each dose, we measured parameters known to change after DDAVP, i.e. factor VIII coagulant activity, bleeding time, von Willebrand factor antigen, ristocetin cofactor and tissue-type plasminogen activator antigen. We found that on average the responses obtained after the second dose of DDAVP were approximately 30% less than those obtained after the first, but were not further reduced after the third and fourth dose. At all time intervals after DDAVP, patients with vWD responded relatively better than patients with haemophilia, and there were fewer vWD patients who responded poorly or became unresponsive. In vWD patients there were no significant changes in the bleeding time responses and in blood pressure and heart rate. The clinical implications of these findings are that repeated doses of DDAVP can be given efficaciously to many patients (particularly to those with vWD), even though responses lower than those seen after the first dose should be expected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419807     DOI: 10.1111/j.1365-2141.1992.tb04598.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Desmopressin : safety considerations in patients with chronic renal disease.

Authors:  Domenic A Sica; Todd W B Gehr
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  The diagnosis and treatment of von Willebrand disease in children.

Authors:  Robert J Klaassen; Jacqueline M Halton
Journal:  Paediatr Child Health       Date:  2002-04       Impact factor: 2.253

3.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

4.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 5.  Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

Authors:  Giancarlo Castaman; Karin Fijnvandraat
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

Review 6.  Desmopressin (DDAVP) and hemostasis.

Authors:  S Lethagen
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

Review 7.  Current controversies in the diagnosis and management of von Willebrand disease.

Authors:  Anne T Neff
Journal:  Ther Adv Hematol       Date:  2015-08

8.  Considerations for epidural anesthesia in a patient with type 1 von Willebrand disease.

Authors:  Koji Hara; Nobuyuki Kishi; Takeyoshi Sata
Journal:  J Anesth       Date:  2009-11-18       Impact factor: 2.078

9.  Evidence-based recommendations on the treatment of von Willebrand disease in Italy.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini; Giancarlo Castaman; Augusto B Federici
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

Review 10.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.